Pfiz­er, Astel­las say Xtan­di drug com­bo re­duces risk of metas­ta­sis, death in prostate can­cer by 58%

Pfiz­er and Astel­las tout­ed more de­tailed da­ta over the week­end on their drug Xtan­di in a type of prostate can­cer, which the com­pa­nies say show the po­ten­tial for Xtan­di to be added to the stan­dard of care if a la­bel ex­pan­sion is ap­proved.

In the Phase III EM­BARK tri­al, the com­pa­nies test­ed out Xtan­di plus le­upro­lide and Xtan­di as a monother­a­py against place­bo plus le­upro­lide in men with non-metasta­t­ic hor­mone-sen­si­tive prostate can­cer with high-risk bio­chem­i­cal re­cur­rence (BCR).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER